Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.73 |
| ▸ | RAB9A | P51151 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | HTT | P42858 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MITF | O75030 | 1/20 | 0.72 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.72 |
| ▸ | ADAMTS5 | Q9UNA0 | 13/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4044460 | 0.95 | NPC1 (0.81) | NPC1RAB9AKMT2AMEN1HTT | |
| SCHEMBL1814816 | 0.93 | ADAMTS5 (0.75) | NPC1RAB9AKMT2AMEN1HTT | |
| SCHEMBL609111 | 0.87 | RAB9A (0.82) | NPC1RAB9AKMT2AMEN1HTT | |
| SCHEMBL1811921 | 0.86 | ADAMTS5 (0.82) | NPC1RAB9AKMT2AMEN1HTT | |
| SCHEMBL608538 | 0.85 | NPC1 (1.00) | NPC1RAB9AKMT2AMEN1HTT | |
| SCHEMBL1814541 | 0.84 | ADAMTS5 (0.78) | NPC1RAB9AKMT2AMEN1HTT | |
| SCHEMBL15783174 | 0.84 | RAB9A (1.00) | NPC1RAB9AKMT2AMEN1HTT | |
| SCHEMBL4044936 | 0.82 | NPC1 (0.82) | NPC1RAB9AKMT2AMEN1HTT | |
| SCHEMBL4036839 | 0.82 | LMNA (0.85) | NPC1RAB9AKMT2AMEN1HTT | |
| SCHEMBL1814805 | 0.82 | KDM4E (0.78) | NPC1RAB9AKDM4EHSP90AA1ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | claimed |
| EP-2056823-A2 | 8-HYDROXYQUINOLINE COMPOUNDS AND METHODS THEREOF | Wyeth (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008024922-A2 | 8-HYDROXYQUINOLINE COMPOUNDS AND METHODS THEREOF | WYETH (US) | 2008-02-28 | — | — | WO | claimed |
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2056823-A2 | 8-HYDROXYQUINOLINE COMPOUNDS AND METHODS THEREOF | Wyeth (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008024922-A2 | 8-HYDROXYQUINOLINE COMPOUNDS AND METHODS THEREOF | WYETH (US) | 2008-02-28 | — | — | WO | disclosed |